ICCC Stock Overview
An animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ImmuCell Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.11 |
| 52 Week High | US$5.82 |
| 52 Week Low | US$3.34 |
| Beta | 0.55 |
| 1 Month Change | -1.16% |
| 3 Month Change | 44.35% |
| 1 Year Change | -1.16% |
| 3 Year Change | -38.36% |
| 5 Year Change | 0.59% |
| Change since IPO | 411.00% |
Recent News & Updates
ImmuCell Corporation (NASDAQ:ICCC) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Dec 04
ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Nov 30Recent updates
ImmuCell Corporation (NASDAQ:ICCC) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Dec 04ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Nov 30Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price
Aug 07ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Aug 10Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price
May 27ImmuCell GAAP EPS of -$0.09, revenue of $3.86M
Aug 11ImmuCell announces preliminary 2Q sales of $3.9M
Jul 07Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?
Sep 15Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation
Jun 10Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?
Mar 15Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?
Jan 22ImmuCell reports FY20 preliminary sales
Jan 07ImmuCell restructures its bank debt
Dec 15ImmuCell EPS beats by $0.04, beats on revenue
Nov 12Shareholder Returns
| ICCC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.3% | -1.1% | -0.3% |
| 1Y | -1.2% | -2.3% | 20.4% |
Return vs Industry: ICCC underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: ICCC underperformed the US Market which returned 22% over the past year.
Price Volatility
| ICCC volatility | |
|---|---|
| ICCC Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ICCC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ICCC's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 77 | Michael Brigham | immucell.com |
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.
ImmuCell Corporation Fundamentals Summary
| ICCC fundamental statistics | |
|---|---|
| Market cap | US$47.77m |
| Earnings (TTM) | -US$3.81m |
| Revenue (TTM) | US$23.84m |
1.9x
P/S Ratio-11.9x
P/E RatioIs ICCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICCC income statement (TTM) | |
|---|---|
| Revenue | US$23.84m |
| Cost of Revenue | US$16.94m |
| Gross Profit | US$6.89m |
| Other Expenses | US$10.71m |
| Earnings | -US$3.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 28.92% |
| Net Profit Margin | -15.99% |
| Debt/Equity Ratio | 41.3% |
How did ICCC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 05:49 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmuCell Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |